## PNEUMOCOCCOSIS

<table>
<thead>
<tr>
<th>Animal Group(s) Affected</th>
<th>Transmission</th>
<th>Clinical Signs</th>
<th>Severity</th>
<th>Treatment</th>
<th>Prevention and Control</th>
<th>Zoonotic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primates, including humans; multiple domestic and lab mammal species; dolphins</td>
<td>Aerosol; direct contact</td>
<td>Primarily respiratory, neurologic, and septic</td>
<td>Asymptomatic to severe</td>
<td>Antibiotics and symptomatic treatment</td>
<td>Vaccine is available for humans. No vaccines have been used routinely for animals. Prevent contact with sick animals or people.</td>
<td>Theoretical</td>
</tr>
</tbody>
</table>

**Fact Sheet compiled by:** Ellen Wiedner  
**Sheet completed on:** 3 August 2011; updated 18 September 2013  
**Fact Sheet Reviewed by:** Jim Wellehan; Ramiro Isaza; Steve Unwin  

**Susceptible animal groups:** Humans, multiple non-human primate species (both wild and captive), dogs, cats, rats, mice, guinea pigs, cattle, horses, dolphins.  

**Causative organism:** *Streptococcus pneumonia* is an alpha-hemolytic strep (encapsulated, facultative anaerobe, optochin sensitive and bile soluble) with more than 90 serotypes  

**Zoonotic potential:** This risk is theoretical but unproven. Animals have developed disease both from human serotypes as well as animal-specific serotypes. One report documented in a human included several clinically ill house pets with *S. pneumoniae*. Suspected reverse zoonosis from a keeper to zoo chimpanzees have occurred.  

**Distribution:** Worldwide.  

**Incubation period:** Carrier status confirmed. With asymptomatic but infective carriers, it is unknown in animals how long carrier state lasts. Clinical disease can occur within 96 hours of exposure.  

**Clinical signs:** Pneumonia, meningitis, sepsis, conjunctivitis, sinusitis, otitis media, other respiratory disease, polyarthritis, endocarditis, pericarditis, and sudden death. Clinical disease often more severe with a viral co-infection.  

**Post mortem, gross, or histologic findings:** Fibrinous bronchopneumonia, pericarditis, necrotizing cerebral vasculitis.  

**Diagnosis:** Bacterial identification of isolates using DNA sequencing, latex agglutination tests and others. Positive Gram staining of respiratory samples with lancet-shaped diplococci. Serotyping recommended.  

**Material required for laboratory analysis:** Respiratory secretions, CSF, or blood. If immediate (< 1hr) transport to laboratory is not possible, samples should be inoculated into growth media and kept cool. The laboratory should be consulted first about appropriate media.  

**Relevant diagnostic laboratories:** Any laboratory that performs cultures and sensitivities on a routine basis can complete testing for this organism. PCR testing can be found at many major commercial and veterinary diagnostic laboratories.  

*Streptococcus* Laboratory  
Centers for Disease Control and Prevention  
1600 Clifton Rd
# PNEUMOCOCCOSIS

Atlanta, GA 30333  
404-639-1237

<table>
<thead>
<tr>
<th>Treatment:</th>
<th>Historically, penicillins were recommended. However, severe multidrug resistance reported in many serotypes to beta-lactam, fluoroquinolone and macrolide antibiotics so culture and sensitivity should be collected and submitted prior to treatment.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention and control:</td>
<td>Vaccination programs for humans have decreased rates of <em>S. pneumoniae</em> severe and fatal disease cases. No vaccines have been tested in animal species. Prevention of contact with infected animals and good hygiene is recommended in zoos and similar animal facilities. If vaccination considered, bacterial typing required before vaccination to confirm polyvalent vaccine applicable.</td>
</tr>
<tr>
<td>Suggested disinfectant for housing facilities:</td>
<td>The bacteria is susceptible to many disinfectants: 70% ethanol, 2% glutaradehyde, 1% sodium hypochlorite and others. However, it can live in sputum at room temperature for one week and in dust particles for up to 25 days.</td>
</tr>
<tr>
<td>Notification:</td>
<td>The disease is reportable nationally. CDC and several states currently conducting surveillance of resistant strains.</td>
</tr>
<tr>
<td>Measures required under the Animal Disease Surveillance Plan:</td>
<td>None at this time.</td>
</tr>
<tr>
<td>Measures required for introducing animals to infected animal:</td>
<td>Do not introduce new animals to an infected animal.</td>
</tr>
<tr>
<td>Conditions for restoring disease-free status after an outbreak:</td>
<td>In human nursing homes, vaccination and treatment of close contacts with prophylactic antibiotics is done. However, no studies on this approach have been documented in animals.</td>
</tr>
</tbody>
</table>
| Experts who may be consulted: | Streptococcus Laboratory  
Centers for Disease Control and Prevention  
1600 Clifton Rd, Atlanta, GA 30333  
404-639-1237  
Fabian Leendertz  
Robert Koch Institute  
Postbox: 650280  
D-13302 Berlin, Germany  
Nordufer 20, 13353  
Berlin, Germany  
+49 (0)30 - 18754-2592  
leendertzf@rki.de |
PNEUMOCOCCOSIS

Vaccine 25: 5390-5398.


